SCHEMBL5111933

SCHEMBL5111933

CCOc1ccc(NC(=O)c2cc(Cl)ccc2NS(=O)(=O)c2ccc(Cl)cc2)c([N+](=O)[O-])c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.71
KMT2A Q03164 5/20 0.71
MEN1 O00255 4/20 0.71
LMNA P02545 4/20 0.71
TDP1 Q9NUW8 2/20 0.71
HTT P42858 2/20 0.71
MCOLN3 Q8TDD5 1/20 0.71
SLC10A6 Q3KNW5 2/20 0.60
SLC10A2 Q12908 1/20 0.60
SLC10A1 Q14973 1/20 0.60
SMN1; SMN2 Q16637 5/20 0.58
GAA P10253 2/20 0.53
ALDH1A1 P00352 2/20 0.53
TP53 P04637 1/20 0.53
HSD17B10 Q99714 1/20 0.53
NPC1 O15118 5/20 0.53
RAB9A P51151 5/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5119272 0.83 KCNMA1 (0.70) MAPTKMT2AMEN1LMNATDP1
SCHEMBL6705937 0.82 RAB9A (0.63) MAPTKMT2AMEN1LMNASMN1; SMN2
SCHEMBL5115416 0.79 SLC10A6 (0.62) MAPTKMT2AMEN1LMNATDP1
SCHEMBL491887 0.77 SLC10A6 (0.57) MAPTKMT2AMEN1LMNATDP1
SCHEMBL5118186 0.77 SLC10A6 (0.62) MAPTKMT2AMEN1LMNAHTT
SCHEMBL5125625 0.76 KCNMA1 (0.71) MAPTKMT2AMEN1LMNATDP1
SCHEMBL5126801 0.75 KCNMA1 (0.61) MAPTKMT2AMEN1LMNASLC10A6
SCHEMBL15176790 0.75 SLC10A6 (1.00) MAPTLMNASLC10A6SLC10A2SLC10A1
SCHEMBL5110940 0.74 SLC10A6 (0.68) KMT2AMEN1LMNASLC10A6SLC10A2
SCHEMBL5119945 0.74 SLC10A2 (0.59) MAPTKMT2AMEN1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351703-B2 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-01 US disclosed
EP-1095015-B1 SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS AVENTIS PHARMA GMBH (DE) 2005-06-01 EP disclosed
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2005-04-14 US disclosed
US-6809089-B2 FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISORDERS SUCH AS HIGH BLOOD PRESSURE, ANGINA PECTORIS, CARDIAC INSUFFICIENCY, THROMBOSES OR ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-10-26 US disclosed
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed
US-6548547-B1 Cardiovascular disorders; hypotensive agents, antiasthmatics, cognition activators AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1A2 MAPT 4869/4885KMT2A 3785/4885MEN1 3114/4885
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1B2 MAPT 4871/4885KMT2A 4155/4885MEN1 3892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.